Prognostic significance of p53 expression in malignant bone tumors: A meta-analysis

Tumor Biology

Volumn 34, Issue 2, 2013, Pages 1037-1043

  Jiang, Liangdong ^a   Tao, Cheng ^a   He, Aiyong ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Ewing's sarcoma; Osteosarcoma; p53 expression; Prognosis

Indexed keywords

PROTEIN P53; TP53 PROTEIN, HUMAN;

ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE FREE SURVIVAL; EWING SARCOMA; GENE OVEREXPRESSION; HUMAN; ONCOGENE; OSTEOSARCOMA; OVERALL SURVIVAL; P53 GENE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SYSTEMATIC REVIEW; TUMOR CLASSIFICATION; BONE TUMOR; CASE CONTROL STUDY; GENETIC PREDISPOSITION; META ANALYSIS; METABOLISM; RISK FACTOR;

BONE NEOPLASMS; CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; OSTEOSARCOMA; RISK FACTORS; SARCOMA, EWING; TUMOR SUPPRESSOR PROTEIN P53;

MLCS; MLOWN;

EID: 84877115402     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-012-0643-5     Document Type: Article

References (41)

1. Ritter J, Bielack SS. Osteosarcoma. Ann Oncol. 2010;21 Suppl 7:vii320-5.
2. Balamuth NJ, Womer RB. Ewing's sarcoma. Lancet Oncol. 2010;11:184-92.
3. Anninga JK, Gelderblom H, Fiocco M, Kroep JR, Taminiau AH, Hogendoorn PC, et al. Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? Eur J Cancer. 2011;47:2431-45.
4. Grimer RJ. Surgical options for children with osteosarcoma. Lancet Oncol. 2005;6:85-92.
5. Janeway KA, Grier HE. Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects. Lancet Oncol. 2010;11:670-8.
6. Yarber JL, Agulnik M. Targeted therapies in bone sarcomas: current approach and future directions. Expert Opin Investig Drugs. 2011;20:973-9.
7. Toomey EC, Schiffman JD, Lessnick SL. Recent advances in the molecular pathogenesis of Ewing's sarcoma. Oncogene. 2010;29:4504-16.
8. Junttila MR, Evan GI. P53 - a Jack of all trades but master of none. Nat Rev Cancer. 2009;9:821-9.
9. Meek DW. Tumour suppression by p53: a role for the DNA damage response? Nat Rev Cancer. 2009;9:714-23.
10. Stiewe T. The p53 family in differentiation and tumorigenesis. Nat Rev Cancer. 2007;7:165-8.
11. Vousden KH, Ryan KM. P53 and metabolism. Nat Rev Cancer. 2009;9:691-700.
12. Vousden KH, Prives C. P53 and prognosis: new insights and further complexity. Cell. 2005;120:7-10.
13. Ozger H, Eralp L, Atalar AC, Toker B, Esberk Ates L, Sungur M, et al. The effect of resistance-related proteins on the prognosis and survival of patients with osteosarcoma: an immunohistochemical analysis. Acta Orthop Traumatol Turc. 2009;43:28-34.
14. Abudu A, Mangham DC, Reynolds GM, Pynsent PB, Tillman RM, Carter SR, et al. Overexpression of p53 protein in primary Ewing's sarcoma of bone: relationship to tumour stage, response and prognosis. Br J Cancer. 1999;79:1185-9.
15. Boulytcheva IV, Soloviev YN, Kushlinskii NE, Mahson AN. Expression of molecular markers in the tumor and survival prognosis in osteosarcoma. Bull Exp Biol Med. 2010;150:237-42.
16. de Alava E, Antonescu CR, Panizo A, Leung D, Meyers PA, Huvos AG, et al. Prognostic impact of p53 status in Ewing sarcoma. Cancer. 2000;89:783-92.
17. Tsai JY, Aviv H, Benevenia J, Chang VT, Patterson F, Aisner S, et al. HER-2/neu and p53 in osteosarcoma: an immunohistochemical and fluorescence in situ hybridization analysis. Cancer Invest. 2004;22:16-24.
18. Oliveira CR, Mendonca BB, Camargo OP, Pinto EM, Nascimento SA, Latorre MR, et al. Classical osteoblastoma, atypical osteoblastoma, and osteosarcoma: a comparative study based on clinical, histological, and biological parameters. Clinics (Sao Paulo). 2007;62:167-74.
19. Lopez-Guerrero JA, Machado I, Scotlandi K, Noguera R, Pellin A, Navarro S, et al. Clinicopathological significance of cell cycle regulation markers in a large series of genetically confirmed Ewing's sarcoma family of tumors. Int J Cancer. 2011;128:1139-50.
20. Gorlick R, Huvos AG, Heller G, Aledo A, Beardsley GP, Healey JH, et al. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol. 1999;17:2781-8.
21. Hu X, Yu AX, Qi BW, Fu T, Wu G, Zhou M, et al. The expression and significance of IDH1 and p53 in osteosarcoma. J Exp Clin Cancer Res. 2010;29:43.
22. Kaseta MK, Khaldi L, Gomatos IP, Tzagarakis GP, Alevizos L, Leandros E, et al. Prognostic value of bax, bcl-2, and p53 staining in primary osteosarcoma. J Surg Oncol. 2008;97:259-66.
23. Uozaki H, Ishida T, Kakiuchi C, Horiuchi H, Gotoh T, Iijima T, et al. Expression of heat shock proteins in osteosarcoma and its relationship to prognosis. Pathol Res Pract. 2000;196:665-73.
24. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815-34.
25. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.
26. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2012. http://www.ohri.ca/programs/clinical-epidemiology/ oxford.asp. Accessed 26 Jul 2012.
27. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-48.
28. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88.
29. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60.
30. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-34.
31. Wang D, Li ZP, Gao FX. Prognosis of intramedullary osteosarcoma by multivariate cox model analysis. Acta Acad Med Mil Tert. 1999;21:259-61.
32. Ye Z, Li W, Fan S, Yang D, Tao H. P53 protein and proliferating cell nuclear antigen expression in osteosarcoma and its relationship with prognosis. Zhejiang Yi Xue. 2000;22:65-7.
33. Lane DP. Cancer. p53, guardian of the genome. Nature. 1992;358:15-6.
34. Koshland Jr DE. Molecule of the year. Science. 1993;262:1953.
35. Soussi T, Wiman KG. Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell. 2007;12:303-12.
36. Kruse JP, Gu W. Modes of p53 regulation. Cell. 2009;137:609-22.
37. Kastan MB. Wild-type p53: tumors can't stand it. Cell. 2007;128:837-40.
38. Aylon Y, Oren M. Living with p53, dying of p53. Cell. 2007;130:597-600.
39. Jamaly S, Khanehkenari MR, Rao R, Patil G, Thakur S, Ramaswamy P, et al. Relationship between p53 overexpression, human papillomavirus infection, and lifestyle in indian patients with head and neck cancers. Tumour Biol. 2012;33:543-50.
40. Liu J, Lin Y, Yang H, Deng Q, Chen G, He J. The expression of p33(ING1), p53, and autophagy-related gene Beclin1 in patients with non-small cell lung cancer. Tumour Biol. 2011;32:1113-21.
41. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature. 1991;351:453-6.